A 5-day regimen of cyclophosphamide, adriamycin, platinum (CAP) in refractory breast cancer.
The activity of the association of cis-platinum with Adriamycin and cyclophosphamide (CAP), as "rescue" chemotherapy for the treatment of refractory and relapsing advanced breast cancer, is presented. Of 42 evaluable patients, previously treated with chemotherapy +/- hormone therapy, 4 (9.5%) achieved a complete response, 15 (35%) had a partial response (CR + PR = 45%). Major toxicity observed was: nausea and vomiting in 95% of patients and leukopenia in 60%.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D012074:Remission Induction
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin